Skinvisible, Inc. (SKVI)
OTCMKTS · Delayed Price · Currency is USD
0.3500
-0.1510 (-30.14%)
Nov 3, 2025, 2:56 PM EST
Skinvisible Revenue
Skinvisible had revenue of $5.00K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $20.00K. In the year 2024, Skinvisible had annual revenue of $20.00K.
Revenue
20.00K
Revenue Growth
n/a
P/S Ratio
135.37
Revenue / Employee
10.00K
Employees
2
Market Cap
2.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.00K | - | - |
| Dec 31, 2023 | 20.00K | -259.30K | -92.84% |
| Dec 31, 2022 | 279.30K | -384.13K | -57.90% |
| Dec 31, 2021 | 663.43K | 387.87K | 140.76% |
| Dec 31, 2020 | 275.56K | 232.39K | 538.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| South Dakota Soybean Processors, LLC | 485.00M |
| Cuisine Solutions | 80.48M |
| Armanino Foods of Distinction | 73.15M |
| Crimson Wine Group | 71.27M |
| Golden Growers Cooperative | 70.82M |
| Reed's | 36.04M |
| Microalliance Group | 22.88M |
| ESG Inc. | 11.87M |
Skinvisible News
- 6 weeks ago - Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments and Patent Protection - Accesswire
- 10 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 10 months ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 1 year ago - Skinvisible Announces Article Highlighting Its Proprietary Transdermal Obesity Formulation Development - Accesswire
- 1 year ago - Promising Data on Transdermal Obesity Formulations Announced by Skinvisible - Accesswire
- 1 year ago - Skinvisible Expands Obesity Patent Application for Transdermal Delivery - Accesswire
- 1 year ago - Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome - Accesswire
- 3 years ago - Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug - Accesswire